'Drug-only' glycopyrronium bromide shows Phase II promise in COPD
This article was originally published in Scrip
Prosonix, a tiny UK company developing a 'drug-only' glycopyrronium bromide product has obtained positive top-line results from a Phase II study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.